Faculty Opinions recommendation of Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.

2013 ◽  
Author(s):  
Victoria Werth
Keyword(s):  
Randomized Controlled Trials ◽  
Plaque Psoriasis ◽  
Global Assessment ◽  
Severity Index ◽  
Biologic Agents ◽  
Controlled Trials ◽  
Physician Global Assessment ◽  
Systematic Analysis ◽  
Severe Plaque Psoriasis ◽  
Randomized Controlled

scholarly journals Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Jing Yang ◽  
Zongming Wang ◽  
Xilin Zhang
Keyword(s):  
Adverse Events ◽  
Randomized Controlled Trials ◽  
Plaque Psoriasis ◽  
Sensitivity Analyses ◽  
Cochrane Library ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
Serious Adverse Events ◽  
Severe Plaque Psoriasis ◽  
Randomized Controlled

Background. To investigate the efficacy and safety of guselkumab in the treatment of moderate-to-severe plaque psoriasis. Methods. A systematic review was undertaken to identify double-blind randomized controlled trials (RCTs). PubMed, Web of Science, Cochrane Library, EMBASE, and Google Scholar databases were searched before 1 March 2020. The odds ratios (ORs) with 95% confidence interval (CI) were calculated. All analyses were conducted with intention-to-treat basis. A range of sensitivity analyses was undertaken. Results. A total of 7 articles contained 1206 plaque psoriasis patients with guselkumab, 585 patients with placebo, and 1250 patients with adalimumab were included. The results indicated that guselkumab had better efficacy than placebo or adalimumab for Psoriasis Area and Severity Index score reductions from baseline of 75% (PASI 75) (OR=61.37, 95% CI=31.15 to 120.91; OR=3.08, 95% CI=2.35 to 4.06), Investigator’s Global Assessment scores of 0 or 1 (IGA 0/1) (OR=65.75, 95% CI=45.54 to 94.95; OR=2.79, 95% CI=2.17 to 3.59), and Dermatology Life Quality Index scores of 0 or 1 (DLQI 0/1) (OR=29.64, 95% CI=18.80 to 46.73; OR=1.86, 95% CI=1.50 to 2.31). The guselkumab had similar safety with placebo or adalimumab about the incidence of adverse events (AEs) (OR=1.05, 95% CI=0.86 to 1.29; OR=0.97, 95% CI=0.79 to 1.19) and serious adverse events (SAEs) (OR=1.03, 95% CI=0.47 to 2.27; OR=0.91, 95% CI=0.44 to 1.87). Meanwhile, there was no statistically significant association of infections and serious infections compared with the placebo or adalimumab group. The guselkumab was more effective and had the similar tolerance. Conclusion. The guselkumab had excellent efficacy and great safety in moderate-to-severe plaque psoriasis, but long-term safety remained to be determined.

Sign in / Sign up

Export Citation Format

Share Document